New eye drug tested for patients failing standard wet AMD treatment
NCT ID NCT05953012
Summary
This was a first-in-human study to check the safety of a new eye injection called PMC-403 for wet age-related macular degeneration (AMD). It involved 17 participants whose vision was still declining despite receiving standard anti-VEGF injections. The main goal was to find the highest safe dose and see how well people tolerated the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASAN Medical Center
Seoul, Songpa-gu, 05505, South Korea
-
Seoul National University Bundang Hospital
Seoul, Bundang-gu, 13620, South Korea
-
Yeungnam University
Daegu, Nam-gu, 42415, South Korea
-
Yonsei University Health System
Seoul, Seodaemun-gu, 03722, South Korea
Conditions
Explore the condition pages connected to this study.